| Name | Title | Contact Details |
|---|
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma Merkel cell carcinoma and cutaneous T-cell lymphoma conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications it is also investigating additional indications and combination therapeutic approaches.
Achieve is a specialty pharmaceutical company committed to advancing cytisine as a widely available treatment option to help people battling nicotine addiction.
Gilva Biotechnology is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EUSA Pharma Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
parteqinnovations is a Kingston, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.